| | 104632-25-9 Basic information More.. |
| Product Name: | Pramipexole Impurity 4 | | Synonyms: | PRAMIPEXOLE HCL;PRAMIPEXOL HCL;(s)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride;PramipexoleDihcl;(S)-2-Amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol2HCltetrahydrobenzothiazol;(s)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine, Dihydrochloride;Pramipexole dihydrochloride
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride;PraMipexole dihydrochlor | | CAS: | 104632-25-9 | | MF: | C10H19Cl2N3S | | MW: | 284.25 | | EINECS: | 629-842-2 | | Mol File: | 104632-25-9.mol |  |
Use
Pramipexole dihydrochloride,(S)-2-amino-6-propylamino-dihydrochloride(Mirapex), is a white to off-white powder soluble in water,slightly soluble in methanol and ethanol, and practically insolublein dichloromethane. Following oral administration,pramipexole is readily absorbed. Pharmacokinetic propertiesdiffer between men and women, with area under the curve(AUC) for each dose level being 35% to 43% greater inwomen, mainly because of a 24% to 27% lower oral clearance.The drug undergoes minimal hepatic biotransformationand is excreted virtually unchanged in the urine by the renaltubular secretion. Pramipexole interacts with drugs excretedby renal tubular secretion (H2-antagonists, diuretics, verapamil,quinidine, quinine), which leads to a decreased clearanceof pramipexole.44,45 Pramipexole is indicated fortreatment of the signs and symptoms of idiopathic PD, aloneor in combination with levodopa. It is also indicated for symptomatictreatment of moderate to severe idiopathic restlesslegs syndrome (RLS).
- Pramipexole Impurity 4
-
- US $10.00-20.00 / kg
- 2023-07-31
- CAS:104632-25-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100000
- Pramipexole Hydrochloride
-
- US $240.00-185.00 / KG
- 2022-11-18
- CAS:104632-25-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 9000kg/per week
|
|
104632-25-9
Recommend Suppliers |
|